The company said it plans to develop its new Chai‑2 platform to design, from square one, completely new antibodies for ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Eli Lilly (LLY) stock hits a 52-week low as concerns over its weight-loss drug trial overshadow strong Q2 2025 results. Read ...

Results from a late-stage trial of Eli Lilly's experimental weight-loss pill were disappointing, sending shares of the drugmaker tumbling.

Eli Lilly's experimental GLP-1 pill showed a 12.4% body weight reduction, less than Novo Nordisk's injectable Wegovy in a ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk shares surged after Eli Lilly's weight-loss pill underperformed expectations in trial results. This setback is ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

Novo Nordisk A/S NVO reported second-quarter 2025 earnings of 97 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 93 cents. The company had reported earnings of ...

The popularity of Novo Nordisk's anti-diabetes and weight-loss treatments Ozempic and Wegovy had once made it a darling of ...